AI assistant
UroGen Pharma Ltd. — Director's Dealing 2025
Aug 27, 2025
32312_dirs_2025-08-27_e328b017-a9a2-4d85-b44d-f1c4d1aba245.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-08-26
Reporting Person: BUTITTA CYNTHIA M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-08-26 | Stock Option (right ot buy) | $19.50 | A | 10000 | Acquired | 2035-08-26 | Ordinary Shares (10000) | Direct |
| 2025-08-26 | Restricted Stock Unit | $ | A | 8000 | Acquired | Ordinary Shares (8000) | Direct |
Footnotes
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.